Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC)

Table 4

Comparison of serum EGFR and pro-GRP levels in the two groups of patients before and after intervention.

Group	Treatment group A ()	Treatment group B ()
Serum EGFR level
Before intervention			0.164	>0.01
After intervention			13.683	<0.01
Serum pro-GRP level
Before intervention			0.058	>0.01
After intervention			20.163	<0.01